Tuesday, June 6, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Protein Sciences Awarded DoD Grant for Novel Adenovirus Vaccine

by Global Biodefense Staff
November 13, 2015

Protein Sciences Corporation this week announced that they have been awarded a Phase I Small Business Innovation Research (SBIR) grant by the U.S. Department of Defense (DoD) for the development of a next generation adenovirus vaccine.

Adenovirus infection is a major cause of acute respiratory disease in U.S. military recruits. The existing vaccine is effective but contains live wild type adenovirus that is capable of being transmitted to others.

Under this award, Protein Sciences will apply its proprietary BEVS platform technology to develop a protein-based vaccine designed to protect against the two major types of adenovirus, Types 4 and 7, without using live adenovirus.

“We are very pleased to be working with the DoD to develop a modern adenovirus vaccine,” said Indresh Srivastava, Vice President of Process and Analytical Development at Protein Sciences and Principal Investigator of the grant.  “Adenovirus affects a large population every year, and our BEVS platform is well suited to address the challenges associated with the existing vaccine.  This program is yet another way that we are continuously working to save lives and improve health.”

Adenoviruses are common causes of respiratory illness.  The incubation period is typically 4-5 days after which people who become infected experience high fever, cough, nasal congestion, headache and chest pain typically lasting 3-10 days.

Source: Protein Sciences, adapted.

Tags: AdenovirusVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC